Advertisement

Reactions Weekly

, Volume 1714, Issue 1, pp 71–71 | Cite as

Bendamustine/obinutuzumab/rituximab

Various toxicities: 6 case reports
Case report
  • 29 Downloads
Author Information

An event is serious (based on the ICH definition) when the patient outcome is:

  • * death

  • * life-threatening

  • * hospitalisation

  • * disability

  • * congenital anomaly

  • * other medically important event

In a retrospective cohort study of 15 patients, six patients (including two men and one woman) [sexes of the remaining patients not stated] were described, who developed infusion-related allergic reaction, neuroborreliosis, fatal pneumonia, allergic reaction, thrombocytopenia or anaemia following treatment with bendamustine, obinutuzumab or rituximab for chronic lymphocytic leukaemia (CLL) or follicular lymphoma (FL) [exactages at reaction onsets and times to reaction onsets not stated; not all routes and outcomes stated].

A patient, who had CLL, was scheduled to receive 6 cycles of bendamustine and obinutuzumab with an interval of 28 days between each cycle. During the first cycle, the patient received infusion of bendamustine 90 mg/m2body surface area at days 1 and 2, and...

Reference

  1. Pirich T, et al. Tolerability of obinutuzumab therapy in patients with rituximab-relapsed/ refractory B-cell malignancies - a retrospective single center cohort study. Oncotarget 9: 29944-29956, No. 52, 6 Jul 2018. Available from: URL: http://doi.org/10.18632/oncotarget.25714 - AustriaCrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Personalised recommendations